Viewing Study NCT05873205

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 3:21 AM
Ignite Modification Date: 2026-04-22 @ 7:49 PM
Study NCT ID: NCT05873205
Status: RECRUITING
Last Update Posted: 2025-07-29
First Post: 2023-05-15
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Open-Label, Phase II Trial of Isatuximab for Patients With Refractory Immune Cytopenias After Allogeneic Hematopoietic Cell Transplantation
Sponsor: Memorial Sloan Kettering Cancer Center
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Blood Cancer View
None Refractory Immune Cytopenias View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Refractory Immune Cytopenias View
None Blood Cancer View
None Isatuximab View
None Allogeneic Hematopoietic Cell Transplantation View
None 23-119 View
None Memorial Sloan Kettering View